The European pharmaceutical industry is to work closely with health economists to develop a standardized framework for evaluating health outcomes.
The European Federation of Pharmaceutical Industries and Associations (EFPIA), Europe’s umbrella organization of pharma trade groups, has partnered with the non-profit International Consortium for Health Outcomes Measurement (ICHOM) to push the agenda forward.
The EFPIA wants to “catalyze the measurement of standardized health outcomes,” to promote value-based, or outcomes-based pricing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze